CoChat

Cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: a systematic review and network meta‐analysis

Open access
Hussein, H., Zaccardi, F., Khunti, K., Seidu, S., Davies, M. J., Gray, L. J. · 2019 · Diabetic Medicine
Cited by 43

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aims: To compare the cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2 ( SGLT 2) inhibitors and glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RA s) in adults with Type 2 diabetes. Methods: Electronic databases were searched from inception to 22 October 2018 for randomized controlled trials designed to assess the cardiovascular efficacy of SGLT 2 inhibitors or GLP ‐1 RA s with regard to a three‐point composite measure of major adverse cardiovascular events (non‐fatal stroke, non‐fatal myocardial infarction and cardiovascular mortality). Cardiovascular and safety data were synthesized using Bayesian network meta‐analyses. Results: Eight trials, including 60 082 participants, were deemed eligible for the network meta‐analysis. Both SGLT 2 inhibitors [hazard ratio 0.86 (95% credible interval 0.74, 1.01]) and GLP ‐1 RA s [hazard ratio 0.88 (95% credible interval 0.78, 0.98)] reduced the three‐point composite measure compared to placebo, with no evidence of differences between them [ GLP ‐1 RA s vs SGLT 2 inhibitors: hazard ratio 1.02 (95% credible interval 0.83, 1.23)]. SGLT 2 inhibitors reduced risk of hospital admission for heart failure compared to placebo [hazard ratio 0.67 (95% credible interval 0.53, 0.85)] and GLP ‐1 RA s [hazard ratio 0.71 (95% credible interval 0.53, 0.93)]. No differences were found between the two drug classes in non‐fatal stroke, non‐fatal myocardial infarction, cardiovascular mortality, all‐cause mortality or safety outcomes. Conclusions: SGLT 2 inhibitors and GLP ‐1 RA s reduced the three‐point major adverse cardiovascular event risk compared to placebo, with no differences between them. Compared with GLP ‐1 RA s and placebo, SGLT 2 inhibitors led to a larger reduction in hospital admission for heart failure risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dme.13898

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 30

  1. 10.1093/eurheartj/ehv239 · DOI · Paper page
  2. 10.1016/S2213-8587(14)70219-0 · DOI · Paper page
  3. 2018, Pharmacologic approaches to glycemic treatment: Standards of medical care in Diabetes ‐ 2018, American Diabetes Association. Diabetes Care, 41, S73
  4. 10.1016/j.phrs.2016.07.001 · DOI
  5. Tran KL, 2017, Overview of glucagon‐like peptide‐1 receptor agonists for the treatment of patients with type 2 diabetes, Am Health Drug Benefits, 10, 178
  6. 10.4158/CS-2017-0153 · DOI · Paper page
  7. 10.1016/S2213-8587(17)30412-6 · DOI · Paper page
  8. 10.1161/JAHA.117.007165 · DOI
  9. 10.1016/j.diabres.2018.03.027 · DOI · Paper page
  10. 10.1016/S2213-8587(16)00052-8 · DOI · Paper page
  11. 10.18549/PharmPract.2017.01.943 · DOI · Paper page
  12. 10.7326/M14-2385 · DOI · Paper page
  13. Shamseer L, 2015, Preferred reporting items for systematic review and meta‐analysis protocols (PRISMA‐P) 2015: elaboration and explanation, BMJ, 349
  14. 10.1111/dom.12849 · DOI · Paper page
  15. 10.7326/M15-1432 · DOI · Paper page
  16. 10.1111/dom.12670 · DOI · Paper page
  17. 10.1136/bmj.d5928 · DOI · Paper page
  18. 10.1056/NEJMoa1611925 · DOI · Paper page
  19. 10.1056/NEJMoa1612917 · DOI · Paper page
  20. 10.1186/s12933-017-0610-y · DOI
  21. 10.17925/EE.2017.13.02.86 · DOI
  22. 10.1016/S2213-8587(14)70031-2 · DOI · Paper page
  23. 10.1186/s12872-016-0260-0 · DOI
  24. 10.1016/j.jacc.2018.03.009 · DOI · Paper page
  25. 10.1161/CIRCULATIONAHA.117.030012 · DOI · Paper page
  26. 10.1007/s11936-017-0522-x · DOI
  27. 10.1056/NEJMoa1812389 · DOI · Paper page
  28. 10.1001/jama.2018.3024 · DOI · Paper page
  29. 10.2337/dc17-0068 · DOI · Paper page
  30. 10.1161/CIRCULATIONAHA.117.026229 · DOI

Cited by

Metadata

Authors
Hussein, H., Zaccardi, F., Khunti, K., Seidu, S., Davies, M. J., & Gray, L. J.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2019-01-30
Volume
36
Issue
4
Pages
444-452
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2910225231
Cited by
43
References
12
FWCI
1.74
Type
journal article
Language
en
Open access
green
Funders
National Institute forHealth Research Collaborations for Leadership in AppliedHealthResearch and Care - EastMidlands

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.